Cortigent, Inc. (CRGT)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	65.00M
Revenue (ttm)	n/a
Net Income	-8.60M
EPS	-1.32
Shares Out	6.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CRGT

Cortigent, through its predecessor Second Sight Medical Products, Inc., is a pioneer in developing targeted neurostimulation systems to help patients recover critical body functions. Our technology combines advanced neuroscience with proprietary microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement. Our first commercial system, “Argus II,” was approved by the U.S. Food & Drug Administration under a Humanitarian Device Exemption and has provided artificial vision to hund...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2022
• Employees: 13
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CRGT

Financial Performance

Data Source: SEC filings Last updated: Aug 20, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error